IGF1 and neoplasm: Moreover, treatment of wild-type mice with an IGF-IR targeting inhibitor, the IGF-Trap, that reduces IGF-I bioavailability and IGF-IR signaling in vivo [21], also significantly reduced HSC activation in response to tumor cells (Figure 3B).